search

BECHILAR * SCIR FL 100ML 3MG / ML

  • MONTEFARMACO OTC SpA
  • 018130029
Final Price €7.50
Quantity
check_circle Available (12 Items)
48h
  Convenient and safe payments

Even with a credit card

  Shipping in 48h-72h all over the world

FREE in Italy over € 39.90

  Fast returns

14 days to reconsider

  Pharmaceutical experience

Always at your service

Home Others products at unbeatable price

MONTEFARMACO OTC SpA

Discover all products

BECHILAR * SCIR FL 100ML 3MG / ML

Therapeutic indications

Cough suppressant with central action. Cough suppressant.

Dosage and method of use

Adults: 1 teaspoon to 3 times a day. Teens and children over 2 years old: half – a coffee spoon 1 to 3 times a day, depending on age. Do not exceed the recommended dose. Do not use in children under the age of two unless otherwise indicated by a doctor.

Contraindications

Hypersensitivity to the active substance or to any of the excipients. Patients with chronic respiratory problems. Patients who are taking or have taken monoamine oxidase inhibitor antidepressants (MAOIs) within the last two weeks.

Side effects

Side effects are rare. They can arise: Nervous system disorders: sleepiness; dizziness. Gastrointestinal disorders: gastrointestinal disorders; nausea; He retched; abdominal discomfort.

Special warnings

If there is no therapeutic response within a few days, consult your doctor; the treatment should not be continued beyond 5-7 days. The product is not recommended in asthmatic patients. Administer with caution in subjects with impaired liver function. Cases of dextromethorphan abuse have been reported. Special care is recommended with adolescents and young adult children, as well as with patients with a history of alcoholism and / or drug or psychoactive substance abuse. Dextromethorphan is metabolised by hepatic cytochrome P450 2D6. The activity of this enzyme is genetically determined. About 10% of the population metabolizes CYP2D6 slowly. Exaggerated and / or prolonged effects of dextromethorphan may occur in poor metabolisers and patients with concomitant use of CYP2D6 inhibitors. Therefore, caution should be exercised in patients who are poor CYP2D6 metabolisers or who use CYP2D6 inhibitors (see also section 4.5). This medicine contains fructose as an excipients therefore patients with rare hereditary problems of fructose intolerance should not take this medicine. This medicine contains Methyl p-hydroxybenzoate and Propyl p-hydroxybenzoate among the excipients therefore it can cause allergic reactions (even delayed).

Pregnancy and breastfeeding

Do not use during pregnancy and lactation, except in case of real need and under direct medical supervision.

Expiry and retention

This medicinal product does not require any special storage conditions

Interactions with other drugs

Administration of dextromethorphan in patients who have received MAO inhibitors can cause serious adverse reactions, including serotonin syndrome. Patients should consult their physician before taking dextromethorphan in case of concomitant therapy with selective serotonin reuptake inhibitor antidepressants or tricyclic antidepressants as serotonin syndrome may occur. Do not use at the same time and in the weeks following antidepressant therapy. It is not advisable to use alcohol during therapy because it can accentuate the undesirable effects of the drug. CYP2D6 inhibitors Dextromethorphan is metabolised by CYP2D6 and has extensive first pass metabolism. Concomitant use of potent inhibitors of the CYP2D6 enzyme can increase the concentrations of dextromethorphan in the body to levels several times higher than normal. This increases the patient's risk of the toxic effects of dextromethorphan (agitation, confusion, tremor, insomnia, diarrhea and respiratory depression) and of developing serotonin syndrome. Potent inhibitors of CYP2D6 are fluoxetine, paroxetine, quinidine and terbinafine. In concomitant use with quinidine, plasma concentrations of dextromethorphan are increased up to 20-fold, resulting in increased adverse effects on the central nervous system of the agent. Amiodarone, flecainide and propafenone, sertraline, bupropion, methadone, cinacalcet, haloperidol, perphenazine and thioridazine also have similar effects on the metabolism of dextromethorphan. If concomitant use of CYP2D6 inhibitors and dextromethorphan is required, the patient should be monitored and the dextromethorphan dose may need to be reduced.

Overdose

Dextromethorphan can cause nausea, vomiting, dizziness, mild somnolence, excitement, gastrointestinal disturbances and respiratory depression at high doses. If undesirable effects other than those described above occur, the patient must notify their doctor.

Active principles

100 mL of syrup (1 bottle) contain: Active ingredient: Dextromethorphan hydrobromide 300 mg Excipients: Methyl p – hydroxybenzoate, Propyl p – hydroxybenzoate, Fructose. For the full list of excipients, see section 6.1

Excipients

One bottle of syrup contains: Fructose, Glycerol, Citric acid monohydrate, Sodium hydroxide, Black cherry flavor, Potassium acesulfame, Methyl p-hydroxybenzoate, Propyl p-hydroxybenzoate, Purified water.

018130029
12 Items